ATHE ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

MELBOURNE, Australia and SAN FRANCISCO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the ShareCafe Hidden Gems webinar on the following dates/times:

AUSTRALIA PARTICIPANTS:

Date:    Friday, 2 February 2024

Time:    12:30 p.m. AEDT / 9:30 a.m. AWST

UNITED STATES PARTICIPANTS:

Date:    Thursday, 1 February 2024

Time:    5:30 p.m. PT / 8:30 p.m. ET

To access further details of the event and to register at no cost, please click , or copy and paste the following link into your internet browser:

An archived replay will be made available following the event.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s web site at

Authorisation & Additional information

This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Investor and Media Contacts:

Australia

Hannah Howlett



U.S.

Remy Bernarda



+1 (415) 203-6386



EN
29/01/2024

Underlying

ATHEALTERITY THERAPEUTICS LIMITED

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALTERITY THERAPEUTICS LIMITED

 PRESS RELEASE
Free
ATHE ALTERITY THERAP...

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report Highlights Granted U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA)Reported positive topline data from open-label Phase 2 clinical trial of ATH434 in MSAPresented additional analyses from the ATH434-201 trial demonstrating continued robust efficacy for the treatment of MSACash balance on 30 June 2025 of A$40.66M MELBOURNE, Australia and SAN FRANCISCO, July 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developi...

July 30, 2025 1 EN
 PRESS RELEASE
Free
ATHE ALTERITY THERAP...

Alterity Therapeutics Reports Positive Topline Data from Open-Label Ph...

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy – ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms – – Neuroimaging Biomarkers Showed Target Engagement and Slowed Brain Atrophy – – ATH434 was Well-Tolerated with Favorable Safety Profile – – Data are Consistent with Phase 2 Double-Blind Trial and Support Advancement of ATH434 in MSA – MELBOURNE, Australia and SAN FRANCISCO, July 28, 2025 (GLOBE NEWSWIRE) -- Alterity The...

July 28, 2025 1 EN
 PRESS RELEASE
Free
ATHE ALTERITY THERAP...

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from...

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study – Peer-reviewed publication in Annals of Clinical and Translational Neurology highlights the use of the MSA Atrophy Index developed to diagnose and track disease progression in Multiple System Atrophy – MELBOURNE, Australia and SAN FRANCISCO, July 24, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an i...

July 24, 2025 1 EN
 PRESS RELEASE
Free
ATHE ALTERITY THERAP...

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

Alterity Therapeutics to Provide Corporate Update in Fireside Chat MELBOURNE, Australia and SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will participate in a Fireside Chat hosted by MST Access on Wednesday, 25 June 2025 in Australia / Tuesday, 24 June 2025 in the United States. Dr. Stamler will provide a corporate update w...

June 23, 2025 1 EN
 PRESS RELEASE
Free
ATHE ALTERITY THERAP...

Alterity Therapeutics Prominently Featured at the International MSA Co...

Alterity Therapeutics Prominently Featured at the International MSA Congress – ATH434 Phase 2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints – – MSA Atrophy Index (MSAai) enhances MSA diagnosis and monitoring – – bioMUSE Study shows higher α- synuclein concentration is associated with greater burden of orthostatic symptoms – MELBOURNE, Australia and SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for ...

May 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch